Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients

被引:18
|
作者
Ben Gacem, R. [1 ]
Hachana, M. [1 ]
Ziadi, S. [1 ]
Amara, K. [1 ]
Ksia, F. [1 ]
Mokni, M. [1 ]
Trimeche, M. [1 ]
机构
[1] Farhat Hached Hosp, Dept Pathol, Sousse 4000, Tunisia
关键词
Breast cancer; BRCA1; BRCA2; Methylation; Tunisia; MAMMARY EPITHELIAL-CELLS; DNA-REPAIR DEFECT; SPORADIC BREAST; PROMOTER METHYLATION; OVARIAN-CANCER; CHROMOSOME; 13Q12-Q13; HEREDITARY BREAST; ESTROGEN-RECEPTOR; TUMORS; HYPERMETHYLATION;
D O I
10.1016/j.canep.2011.09.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to evaluate the contribution of the BRCA1 and BRCA2 promoter methylation in the pathogenesis of sporadic breast cancer in Tunisian patients. Methods: Breast carcinoma tissues (n = 117) and available paired normal breast tissues (n = 65) from Tunisian women who had no family history were investigated for the methylation status of BRCA1 and BRCA2 promoters using methylation-specific PCR. Breast specimens from women without carcinoma (16 fibroadenomas and 5 mastopathies) were used as control. Results: Hypermethylation of BRCA1 and BRCA2 promoters was detected respectively in 60.7% and 69.2% of the carcinoma tissues, and in only 7.7% and 4.6% of the paired normal breast tissues. None of the fibroadenomas and mastopathies showed hypermethylation. Correlations were found between BRCA1 and BRCA2 hypermethylation and decrease in their mRNA expression (p = 0.02 and p = 0.009, respectively). Moreover, BRCA1 methylation correlates with patients age (p = 0.01) and triple negative (ER-, PR-, HER2-) tumors (p = 0.01). Patients with methylated BRCA1 and/or BRCA2 had a significant prolonged survivals compared to those with unmethylated tumors (p = 0.002). Conclusion: Our results suggest an important role of BRCA1 and BRCA2 promoter methylation in breast cancer development in the Tunisian population. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 50 条
  • [21] Breast surveillance of patients with BRCA1 and BRCA2 mutations
    Warner E.
    Current Breast Cancer Reports, 2013, 5 (3) : 255 - 261
  • [22] The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Ramus, Susan J.
    Gayther, Simon A.
    MOLECULAR ONCOLOGY, 2009, 3 (02) : 138 - 150
  • [23] Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan
    Liede, A
    Malik, IA
    Aziz, Z
    de los Rios, P
    Kwan, E
    Narod, SA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (03) : 595 - 606
  • [24] Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer
    Chan, KYK
    Ozçelik, H
    Cheung, ANY
    Ngan, HYS
    Khoo, US
    CANCER RESEARCH, 2002, 62 (14) : 4151 - 4156
  • [25] GENETIC VARIATION OF THE BRCA1 AND BRCA2 GENES IN MACEDONIAN PATIENTS
    Maleva, I
    Madjunkova, S.
    Bozhinovski, G.
    Smickova, E.
    Kondov, G.
    Spiroski, Z.
    Arsovski, A.
    Plaseska-Karanfilska, D.
    BALKAN JOURNAL OF MEDICAL GENETICS, 2012, 15 : 81 - 85
  • [26] Genomic rearrangements in the BRCA1 and BRCA2 genes
    Mazoyer, S
    HUMAN MUTATION, 2005, 25 (05) : 415 - 422
  • [27] Founder mutations in BRCA1 and BRCA2 genes
    Ferla, R.
    Calo, V.
    Cascio, S.
    Rinaldi, G.
    Badalamenti, G.
    Carreca, I.
    Surmacz, E.
    Coliucci, G.
    Bazan, V.
    Russo, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 93 - 98
  • [28] Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
    Loman, N
    Johannsson, O
    Bendahl, PO
    Borg, Å
    Fernö, M
    Olsson, H
    CANCER, 1998, 83 (02) : 310 - 319
  • [30] The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2
    Pfeffer, Claire M.
    Ho, Benjamin N.
    Singh, Amareshwar T. K.
    CANCER GENOMICS & PROTEOMICS, 2017, 14 (05) : 293 - 298